Epic Sciences to present at Molecular Medicine Tri-Con 2016.
Epic Sciences, Inc., announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Molecular Medicine Tri-Con 2016, taking place at the Moscone Convention Center, San Francisco.
Avera Medical Group and Epic Sciences collaborate on cancer precision medicine clinical trials.
Epic Sciences, Inc. and Avera Medical Group announced today a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials.
Epic Sciences receives CAP accreditation.
Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory.
Circulating tumor cells linked with treatment resistance and response in prostate cancer patients.
Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.
Epic Sciences enters into 35th pharma collaboration to advance companion diagnostics for new targeted therapeutics.
Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today that it has signed its 35th collaboration agreement with pharmaceutical companies.
Epic Sciences' chief scientific officer named leading global thinker by Foreign Policy magazine.
Epic Sciences' Chief Scientific Officer Dena Marrinucci, Ph.D., was named today by Foreign Policy magazine as one of this year’s 100 Leading Global Thinkers. Marrinucci will be honored at a gala in Washington, D.C. this evening.
Epic Sciences partners with University of Pennsylvania's Abramson Cancer Center on cancer therapy discoveries through liquid biopsy.
Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells (CTCs) at a single cell resolution, that are predictive of response to personalized cancer therapeutics.